These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24831352)

  • 1. Exhaled NO predicts cyclophosphamide response in scleroderma-related lung disease.
    Tiev KP; Rivière S; Hua-Huy T; Cabane J; Dinh-Xuan AT
    Nitric Oxide; 2014 Aug; 40():17-21. PubMed ID: 24831352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
    van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
    Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
    Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
    Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.
    Balbir-Gurman A; Yigla M; Guralnik L; Hardak E; Solomonov A; Rozin AP; Toledano K; Dagan A; Bishara R; Markovits D; Nahir MA; Braun-Moscovici Y
    Isr Med Assoc J; 2015 Mar; 17(3):150-6. PubMed ID: 25946765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.
    Iudici M; Cuomo G; Vettori S; Bocchino M; Sanduzzi Zamparelli A; Cappabianca S; Valentini G
    Semin Arthritis Rheum; 2015 Feb; 44(4):437-44. PubMed ID: 25282395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease.
    Tzelepis GE; Plastiras SC; Karadimitrakis SP; Vlachoyiannopoulos PG
    Clin Exp Rheumatol; 2007; 25(5):734-9. PubMed ID: 18078622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
    Bérezné A; Valeyre D; Ranque B; Guillevin L; Mouthon L
    Ann N Y Acad Sci; 2007 Sep; 1110():271-84. PubMed ID: 17911442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.
    Mittoo S; Wigley FM; Wise R; Xiao H; Hummers L
    Arthritis Rheum; 2007 Dec; 56(12):4195-202. PubMed ID: 18050251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
    Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P
    Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of exhaled nitric oxide to detect interstitial lung disease in systemic sclerosis.
    Tiev KP; Coste J; Ziani M; Aubourg F; Cabane J; Dinh-Xuan AT
    Sarcoidosis Vasc Diffuse Lung Dis; 2009 Jul; 26(1):32-8. PubMed ID: 19960786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
    Bérezné A; Ranque B; Valeyre D; Brauner M; Allanore Y; Launay D; Le Guern V; Kahn JE; Couderc LJ; Constans J; Cohen P; Mahr A; Pagnoux C; Hachulla E; Kahan A; Cabane J; Guillevin L; Mouthon L
    J Rheumatol; 2008 Jun; 35(6):1064-72. PubMed ID: 18464307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
    Furuya Y; Kuwana M
    J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase.
    Airò P; Danieli E; Rossi M; Frassi M; Cavazzana I; Scarsi M; Grottolo A; Franceschini F; Zambruni A
    Clin Exp Rheumatol; 2007; 25(2):293-6. PubMed ID: 17543156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of cyclophospamide in the treatment of interstitial lung disease associated with systemic sclerosis.
    Espinosa G; Simeón CP; Plasín MÁ; Xaubet A; Muñoz X; Fonollosa V; Cervera R; Vilardell M
    Arch Bronconeumol; 2011 May; 47(5):239-45. PubMed ID: 21458128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma.
    Domiciano DS; Bonfá E; Borges CT; Kairalla RA; Capelozzi VL; Parra E; Christmann RB
    Clin Rheumatol; 2011 Feb; 30(2):223-9. PubMed ID: 20544245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study.
    Theodore AC; Tseng CH; Li N; Elashoff RM; Tashkin DP
    Chest; 2012 Sep; 142(3):614-621. PubMed ID: 22156609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
    Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G;
    Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-reactive protein and ground-glass opacity as predictors for intractable interstitial lung disease in patients with systemic sclerosis under cyclophosphamide treatment regardless of concomitant glucocorticoids.
    Yoshida Y; Sugimoto T; Hosokawa Y; Suma H; Kobayashi H; Ishitoku M; Kohno H; Tokunaga T; Watanabe H; Mokuda S; Nojima T; Hirata S; Sugiyama E
    Mod Rheumatol; 2022 Jan; 32(1):141-148. PubMed ID: 33775207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II.
    Volkmann ER; Tashkin DP; Sim M; Li N; Khanna D; Roth MD; Clements PJ; Hoffmann-Vold AM; Furst DE; Kim G; Goldin J; Elashoff RM
    J Rheumatol; 2019 Oct; 46(10):1316-1325. PubMed ID: 30770517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of pulse oral cyclophosphamide therapy in scleroderma interstitial lung disease.
    Arunsurat I; Mahakkanukrauh A; Foocharoen C; Suwannaroj S; Nanagara R;
    Clin Rheumatol; 2021 Jan; 40(1):205-211. PubMed ID: 32519048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.